Phase I Study of OriC902 in Treatment of Advanced HCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
HCC
Interventions
DRUG

OriC902

Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent preparation of CAR T cells

Trial Locations (2)

100000

RECRUITING

Beijing GoBroad Hospital, Beijing

NOT_YET_RECRUITING

Peking University Cancer Hospital & Institute, Beijing

Sponsors
All Listed Sponsors
collaborator

OriCell Therapeutics Co., Ltd.

INDUSTRY

lead

Peking University

OTHER